Seminars in Oncology Nursing
Volume 23 , Pages S11-S14 , November 2007

Emerging Agents for the Treatment of Advanced Bladder Cancer

  • Elizabeth Manchen

      Affiliations

    • Corresponding Author InformationAddress correspondence to Elizabeth Manchen, RN, MS, OCN®, Genitourinary Research Nurse Associate, Section of Hematology/Oncology, University of Chicago, 5841 S. Maryland Ave, MC2115, Chicago, IL 60637

References 

  1. Meliani E, Lapini A, Serni S, et al. Gemcitabine plus cisplatin in adjuvant regimen for bladder cancer. Toxicity evaluation. Urol Int. 2003;71:37–40
  2. Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC3098/Intergroup Study. [abstract LBA5030] J Clin Oncol. 2007;25:LBA5030
  3. Culine S, Theodore C, De Santis M, et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer. 2006;94:1395–1401
  4. Dodd PM, McCaffrey JA, Herr H, et al. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol. 1999;17:2546–2552
  5. Siefker-Radtke AO, Millikan RE, Tu SM, et al. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol. 2002;20:1361–1367
  6. Barjorin DF, Bochner BH, Sandler HM, et al. Changing Paradigms in Advanced Bladder Cancer. American Society of Clinical Oncology 2005 Educational Book. Alexandria, VA: American Society of Clinical Oncology; 2005;pp 330-350

PII: S0749-2081(07)00095-2

doi: 10.1016/j.soncn.2007.10.008

Seminars in Oncology Nursing
Volume 23 , Pages S11-S14 , November 2007

Article Tools

* Image Usage & Resolution